Examples of Potential New Product in a sentence
Within ten (10) days following an election to participate in such [CONFIDENTIAL TREATMENT REQUESTED] Potential New Product, IDEC shall pay Genentech the opt-in fee set forth in Section 7.1(b)(iv).
For a period of thirty (30) days following an election by IDEC to participate in an [CONFIDENTIAL TREATMENT REQUESTED] Potential New Product, Genentech and IDEC shall use good faith efforts to agree upon the amount of the opt-in fee IDEC shall pay in order to obtain the right to include such [CONFIDENTIAL TREATMENT REQUESTED] Potential New Product as a New Product hereunder; such amount to be [CONFIDENTIAL TREATMENT REQUESTED] cost of such product attributable to rights in the United States.
IDEC shall have sixty (60) days from the date of Genentech’s notice to IDEC of the availability of a Potential New Product to provide written notice to Genentech that it elects to participate in the development and commercialization of such Potential New Product.
From and after the date of the payment of such fee, such [CONFIDENTIAL TREATMENT REQUESTED] Potential New Product shall be deemed a New Product under this Agreement, and IDEC shall have the right to participate with Genentech with respect to such product [CONFIDENTIAL TREATMENT REQUESTED].
With respect to [CONFIDENTIAL TREATMENT REQUESTED] Potential New Products, [CONFIDENTIAL TREATMENT REQUESTED], Genentech will provide to IDEC a summary of Genentech’s rights (and IDEC’s potential rights) to develop and commercialize such [CONFIDENTIAL TREATMENT REQUESTED] Potential New Product, as well as relevant information about the product, including preclinical and clinical data and reports [CONFIDENTIAL TREATMENT REQUESTED].
Genentech shall pay IDEC a [CONFIDENTIAL TREATMENT REQUESTED] royalty on Royalty-Bearing Sales in the Licensed Territory of G2H7 and each other New Product; provided however, that no such royalty shall be due on any [CONFIDENTIAL TREATMENT REQUESTED] Potential New Product that was deemed a New Product pursuant to Section 2.5(b)(ii), nor on any Third Party Anti-CD20 Product for which IDEC enters into a written agreement with Genentech pursuant to Section 2.6.
IDEC shall have sixty (60) days from the date of Genentech’s notice to IDEC of such development assessment package to provide written notice to Genentech that it elects to participate in the development and commercialization of such [CONFIDENTIAL TREATMENT REQUESTED] Potential New Product.
If the Parties are unable to agree upon the amount of the opt-in fee for such [CONFIDENTIAL TREATMENT REQUESTED] Potential New Product, either Party may, by written notice to the other, have such matter referred to an independent investment banker, mutually agreeable to both Parties, to determine the amount of CONFIDENTIAL TREATMENT such opt-in fee; such determination to be binding upon both Parties.
CONFIDENTIAL TREATMENT From and after the date of the payment of such fee, such [CONFIDENTIAL TREATMENT REQUESTED] Potential New Product shall be deemed a New Product under this Agreement, and the Parties shall [CONFIDENTIAL TREATMENT REQUESTED].
Within ten (10) days following an election to participate in a [CONFIDENTIAL TREATMENT REQUESTED] Potential New Product, IDEC shall pay Genentech the opt-in fee set forth in Section 7.1(b)(ii) or (iii), as the case may be.